Document Type : Original Article(s)
Authors
- Mohammad Sadegh Rezai 1
- Hiva Ghasempouri 2
- Ozra Asqary Marzidareh 2
- Jamshid Yazdani Cherati 3
- Ghasem Rahmatpour Rokni 4
1 Pediatric Infectious Diseases Superspecialist, Infectious Diseases Research Center with focus on Nosocomial Infections, Mazandaran University of Medical Sciences, Sari, Ira
2 General physician, Mazandaran University of Medical Sciences, Sari, Iran
3 Epidemiologist, Department of Biostatistics, Health Sciences Research Center, Mazandaran University of Medical Sciences, Sari, Iran
4 General physician, Mazandaran University of Medical Sciences, Sari, Iran and Dermatologist, Clinical Research Development Unit of Bou-Ali Sina Hospital, Mazandaran University of Medical Sciences, Sari, Iran
Abstract
Background: Common resistant-to-therapy warts pose a challenge to both clinicians and patients. Among many destructive and immunotherapeutic options, no single, fully effective treatment has been suggested yet. Many investigations, including those using intralesional antigen administrations, have demonstrated that cellular immunity plays a major role in the clearance of human papilloma virus (HPV) infection. The aim of the present study was to evaluate the effects of the intralesional injection of the measles–mumps–rubella (MMR) vaccine into resistant-to- treatment palmoplantar warts and its complications.Methods: In this single-blind, randomized, controlled clinical trial, 60 cases with resistant-to-therapy palmoplantar warts referring to the Dermatology Clinic of Bou-Ali Sina Hospital of Sari between June 2015 and 2016 were randomly assigned to 2 equal groups: the MMR Group received intralesional MMR and the Placebo Group was given saline injection. The injections were administered at 2-week intervals until complete clearance was achieved or for a maximum of 5 injections (
Keywords
)